MX2022016097A - Procedimientos para detectar y predecir neoplasia epitelial cervical de grado 3 (cin3) y/o cáncer. - Google Patents

Procedimientos para detectar y predecir neoplasia epitelial cervical de grado 3 (cin3) y/o cáncer.

Info

Publication number
MX2022016097A
MX2022016097A MX2022016097A MX2022016097A MX2022016097A MX 2022016097 A MX2022016097 A MX 2022016097A MX 2022016097 A MX2022016097 A MX 2022016097A MX 2022016097 A MX2022016097 A MX 2022016097A MX 2022016097 A MX2022016097 A MX 2022016097A
Authority
MX
Mexico
Prior art keywords
cancer
individual
cin3
cervical
predicting
Prior art date
Application number
MX2022016097A
Other languages
English (en)
Inventor
Martin Widschwendter
James Barrett
Allison Jones
Iona Evans
Original Assignee
Ucl Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2009225.0A external-priority patent/GB202009225D0/en
Priority claimed from GBGB2107421.6A external-priority patent/GB202107421D0/en
Application filed by Ucl Business Ltd filed Critical Ucl Business Ltd
Publication of MX2022016097A publication Critical patent/MX2022016097A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/708—Specific hybridization probes for papilloma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/165—Mathematical modelling, e.g. logarithm, ratio
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se refiere a ensayos para predecir la presencia, ausencia o desarrollo de CIN3 y/o cáncer, en particular cáncer cervical o endometrial, con máxima preferencia cáncer cervical, en un individuo, particularmente cáncer cervical y endometrial, mediante la determinación del estado de metilación de ciertas CpG en una población de moléculas de ADN en una muestra que se ha tomado del individuo, obteniendo un valor de índice en base al estado de metilación de las ciertas CpG, y prediciendo la presencia, ausencia o desarrollo de CIN3 y/o cáncer, en particular cáncer cervical o endometrial, con máxima preferencia cáncer cervical, en el individuo en base al valor de índice de cáncer. La invención se refiere además a un procedimiento de tratamiento y/o prevención de cáncer en un individuo, en particular cáncer cervical y endometrial, comprendiendo el procedimiento evaluar la presencia, ausencia o desarrollo de CIN3 y/o cáncer, en particular cáncer cervical o endometrial, con máxima preferencia cáncer cervical, en un individuo mediante la realización de los ensayos de la invención, seguido de la administración al individuo de uno o más tratamientos o medidas terapéuticas en base a la evaluación. La invención además proporciona un procedimiento de supervisión del estado de CIN3 y/o cáncer de un individuo de acuerdo con los cambios en el valor de índice de cáncer del individuo en el tiempo. La invención además se refiere a matrices que son adecuadas para realizar los ensayos de la invención.
MX2022016097A 2020-06-17 2021-06-17 Procedimientos para detectar y predecir neoplasia epitelial cervical de grado 3 (cin3) y/o cáncer. MX2022016097A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2009225.0A GB202009225D0 (en) 2020-06-17 2020-06-17 Methods for detecting and predicting grade 3 cervical epithelial neoplasia (cin3) and/or cancer
GBGB2107421.6A GB202107421D0 (en) 2021-05-25 2021-05-25 Methods of detecting and predicting grade 3 cervical epithelial neoplasia (CIN3) and/or cancer
PCT/GB2021/051537 WO2021255460A1 (en) 2020-06-17 2021-06-17 Methods for detecting and predicting grade 3 cervical epithelial neoplasia (cin3) and/or cancer

Publications (1)

Publication Number Publication Date
MX2022016097A true MX2022016097A (es) 2023-04-20

Family

ID=76730906

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016097A MX2022016097A (es) 2020-06-17 2021-06-17 Procedimientos para detectar y predecir neoplasia epitelial cervical de grado 3 (cin3) y/o cáncer.

Country Status (11)

Country Link
US (1) US20240060136A1 (es)
EP (1) EP4168588A1 (es)
JP (1) JP2023530984A (es)
KR (1) KR20230051478A (es)
CN (1) CN116194596A (es)
AU (1) AU2021291614A1 (es)
BR (1) BR112022025848A2 (es)
CA (1) CA3187000A1 (es)
IL (1) IL299143A (es)
MX (1) MX2022016097A (es)
WO (1) WO2021255460A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013033627A2 (en) * 2011-09-01 2013-03-07 The Regents Of The University Of California Diagnosis and treatment of arthritis using epigenetics
US11352672B2 (en) * 2014-09-15 2022-06-07 Garvan Institute Of Medical Research Methods for diagnosis, prognosis and monitoring of breast cancer and reagents therefor
BR112019018743A2 (pt) * 2017-03-10 2020-05-05 Self-Screen B.V. classificador de metilação para detecção de cânceres invasivos induzidos por hpv, cânceres ginecológicos e anogenitais não induzidos por hpv e suas lesões precursoras de alto grau
CA3121886A1 (en) * 2018-12-04 2020-06-11 Hkg Epitherapeutics Limited Dna methylation biomarkers for early detection of cervical cancer

Also Published As

Publication number Publication date
EP4168588A1 (en) 2023-04-26
JP2023530984A (ja) 2023-07-20
CN116194596A (zh) 2023-05-30
BR112022025848A2 (pt) 2023-01-10
AU2021291614A1 (en) 2023-02-02
CA3187000A1 (en) 2021-12-23
KR20230051478A (ko) 2023-04-18
US20240060136A1 (en) 2024-02-22
IL299143A (en) 2023-02-01
WO2021255460A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
Jeschke et al. DNA methylation–based immune response signature improves patient diagnosis in multiple cancers
Zhang et al. Clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinoma
Evans‐Galea et al. FXN methylation predicts expression and clinical outcome in Friedreich ataxia
Barazani et al. Functional sperm testing and the role of proteomics in the evaluation of male infertility
Varey et al. Neurotropic melanoma: an analysis of the clinicopathological features, management strategies and survival outcomes for 671 patients treated at a tertiary referral center
US20210404003A1 (en) Dna methylation and genotype specific biomarker for predicting post-traumatic stress disorder
Parker et al. Evaluation of B7-H3 expression as a biomarker of biochemical recurrence after salvage radiation therapy for recurrent prostate cancer
Sun et al. Overexpression of PKMYT1 indicates the poor prognosis and enhances proliferation and tumorigenesis in non-small cell lung cancer via activation of Notch signal pathway.
CN113838531B (zh) 一种基于转录组数据和机器学习策略评估细胞衰老程度的方法
Freire-Aradas et al. A common epigenetic clock from childhood to old age
Wang et al. Validation of DAB2IP methylation and its relative significance in predicting outcome in renal cell carcinoma
WO2014082067A1 (en) Methods and compositions for diagnosing and treating gastric cancer
AU2014287090A1 (en) A DNA methylation and genotype specific biomarker of suicide attempt and/or suicide ideation
Li et al. Integrative analysis of DNA methylation and gene expression identify a six epigenetic driver signature for predicting prognosis in hepatocellular carcinoma
Wilson et al. Utility of DNA methylation to assess placental health
Krishnan et al. Computational methods reveal novel functionalities of PIWI-interacting RNAs in human papillomavirus-induced head and neck squamous cell carcinoma
Charras et al. DNA methylation patterns in CD8+ T cells discern psoriasis from psoriatic arthritis and correlate with cutaneous disease activity
Dean et al. The association between telomere length and mortality in Bangladesh
Byzia et al. Recurrent transcriptional loss of the PCDH17 tumor suppressor in laryngeal squamous cell carcinoma is partially mediated by aberrant promoter DNA methylation
Wan et al. Comprehensive analysis of cancer hallmarks in cutaneous melanoma and identification of a novel unfolded protein response as a prognostic signature
Cai et al. Tamoxifen therapy benefit predictive signature coupled with prognostic signature of post-operative recurrent risk for early stage ER+ breast cancer
CN116261601A8 (zh) 用于检测和预测癌症的方法
MX2022016097A (es) Procedimientos para detectar y predecir neoplasia epitelial cervical de grado 3 (cin3) y/o cáncer.
MX2022016100A (es) Procedimientos para la detección y predicción de neoplasia epitelial cervical de grado 3 (cin3) y/o cáncer.
Murray et al. Limited improvement of incorporating primary circulating prostate cells with the CAPRA score to predict biochemical failure-free outcome of radical prostatectomy for prostate cancer